LY-311727

• UNSPSC Description:

  LY-311727 is a potent secretory non-pancreatic phospholipase A2 (sPLA2) inhibitor (IC50 2). sPLA2 is an important proinflammatory enzyme[1][2].

• Target Antigen:

  Phospholipase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ly-311727.html

• Purity:

  99.0

• Solubility:

  DMSO : 30 mg/mL (ultrasonic)

• Smiles:

  NC(CC1=C(CC)N(CC2=CC=CC=C2)C3=C1C=C(OCCCP(O)(O)=O)C=C3)=O

• Molecular Weight:

  430.43

• References & Citations:

  [1]R W Schevitz, et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 1995 Jun;2(6):458-65.|[2]N Fox, et al. Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors. Eur J Pharmacol. 1996 Jul 18;308(2):195-203.|[3]M Murakami, et al. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem. 1998 Jun 5;273(23):14411-23.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  164083-84-5